Veeraraghavan, Jamunarani http://orcid.org/0000-0002-9524-9487
Gutierrez, Carolina
Sethunath, Vidyalakshmi
Mehravaran, Sepideh
Giuliano, Mario
Shea, Martin J.
Mitchell, Tamika
Wang, Tao http://orcid.org/0000-0003-1957-7160
Nanda, Sarmistha
Pereira, Resel
Davis, Robert
Goutsouliak, Kristina
Qin, Lanfang
De Angelis, Carmine http://orcid.org/0000-0003-1158-4630
Diala, Irmina
Lalani, Alshad S.
Nagi, Chandandeep
Hilsenbeck, Susan G.
Rimawi, Mothaffar F. http://orcid.org/0000-0002-4284-5656
Osborne, C. Kent
Schiff, Rachel http://orcid.org/0000-0003-1696-5213
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-19-145)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-17-1-0580, W81XWH-17-1-0579)
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA125123)
Article History
Received: 5 November 2020
Accepted: 3 May 2021
First Online: 27 May 2021
Competing interests
: C.G.: Research grant from Ventana. M.G.: speaker bureau for Novartis, Eli Lilly, Pfizer, Celgene, Eisai, and AstraZeneca; accommodation and travel support from Roche and Pfizer. C.D.A.: consultant/advisory board member for Novartis, Eli Lilly, and Pfizer; Research grant from Novartis (to the Institution). M.F.R.: research support from GSK (to institution); consulting with Genentech, Novartis, Daiichi, and Macrogenics. I.D.: employee of Puma Biotechnology Inc. A.S.L.: employee of Puma Biotechnology Inc. C.K.O.: research funding from AstraZeneca and GlaxoSmithKline; advisory boards for Tolmar Pharmaceuticals, Genentech, and AstraZeneca; DMC for Eli Lilly; Stockholder of GeneTex. R.S.: research funding from AstraZeneca, GlaxoSmithKline, Puma Biotechnology Inc. (to the institution), and Gilead Sciences; past ad hoc advisory committee member for Eli Lilly; and consulting/advisory committee member for Macrogenics. The remaining authors declare no competing interests